ISPH Pharmaceuticals, Inc. (NASDAQ:ISPH) witnessed an unusual volume of 23.69 million shares during last trade where it holds an average trading capacity of 633,536 shares. ISPH shares opened at $3.76 reached intraday low of $3.43 and went -58.72% down to close at $3.47.
ISPH shares price distanced by -55.41% from 20 days average, -52.72% from SMA50 and -42.86% from SMA200. Similarly, the shares performance calculated for a week provided positive result of -59.68%, -51.16% for a month and Year-to-Date performance was -58.72%.
The company has an Enterprise Value of $628.29 million where in most recent quarter it had a total cash in hand amounted to $98.65 million with a 1.17 book value per share. The beta value of 0.99 signifies to the movement of price with the market condition. The percentage of holdings by the insider in ISPH is 0.02%.
Its past twelve months decrease in return from assets was 20.33%, return on equity remained -31.12% and return on investments reached -29.05%. The net profit margin in last 12 months fell -31.94% and in most recent quarter debt to equity of 0.11 giving a view of company’s reliance on taking loans.
The Company in past 12 months achieved Gross Profit of $80.89 million where the year to year quarterly revenue growth was 6.20% and Net Income Available to Shareholders reached to $-33.76 million with the diluted EPS of -0.41.
Inspire Pharmaceuticals, Inc., a biopharmaceutical company, focuses on researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective for the treatment of bacterial conjunctivitis; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease.
